

April 28–30, 2005

Natcher Conference Center
National Institutes of Health
Bethesda, MD

Skeletal Complications of Malignancy **IV**

Jointly sponsored by:



The Paget Foundation

*For Paget's Disease of Bone
and Related Disorders*

NATIONAL
CANCER
INSTITUTE

UNIVERSITY OF VIRGINIA SCHOOL OF MEDICINE
**UNIVERSITY
of VIRGINIA**
HEALTH SYSTEM

Skeletal Complications of Malignancy IV

Please contact the symposium organizers
for more information at:

The Paget Foundation
120 Wall Street, Suite 1602
New York, NY 10005
(T) 212-509-5335
(F) 212-509-8492
www.paget.org
E-mail: Pagetsym@aol.com

Dear Colleague,

International leaders in the cancer and bone fields will gather April 28-30, 2005 for the only medical meeting in North America that specifically focuses on the skeletal complications of malignancy. On behalf of the Paget Foundation, the National Cancer Institute and the University of Virginia School of Medicine, we hope you will plan to attend.

The symposium format includes plenary sessions, abstract presentations, and poster displays along with networking opportunities for industry colleagues and professionals. Continuing Medical Education (CME) credit will be provided by the University of Virginia School of Medicine.

This three-day symposium will provide clinicians and basic researchers with cutting edge presentations on the pathophysiology, diagnosis and treatment of bone metastasis from breast cancer, prostate cancer and myeloma. Important areas to be discussed include the role of interaction between tumors and the bone microenvironment in the metastatic process, use of new imaging techniques, pathogenesis and treatment of bone pain from metastasis as well as management of treatment induced bone loss. In addition, the pathogenesis, diagnosis and treatment of osteosarcomas will be addressed.

This symposium is supported by educational grants from:

 **NOVARTIS**

 **Abbott Laboratories**

 **Bristol-Myers Squibb Company**









Genentech





Program Committee Co-Chairs:

Theresa A. Guise, M.D.
Charlottesville, VA

Allan Lipton, M.D.
Hershey, PA

G. David Roodman, M.D., Ph.D.
Pittsburgh, PA

Program Committee

Nick Athanasou, Ph.D., MBBS
Oxford, United Kingdom

Jean-Jacques Body, M.D., Ph.D.
Brussels, Belgium

David Goltzman, M.D.
Montreal, Canada

Janet Hock, Ph.D.
Indianapolis, IN

Gabriel N. Hortobagyi, M.D., FACP
Houston, TX

Laurie McCauley, Ph.D., D.D.S.
Ann Arbor, MI

Suresh Mohla, Ph.D.
Bethesda, MD

Frederick R. Singer, M.D.
Santa Monica, CA

Matthew Smith, M.D., Ph.D.
Boston, MA

Howard Soule, Ph.D.
Santa Monica, CA

Gabri Van der Pluijm, Ph.D.
Leiden, The Netherlands

Robert Vessella, Ph.D.
Seattle, WA

Kristy Weber, M.D.
Baltimore, MD

Skeletal Complications of Malignancy

General Information

The Paget Foundation for Paget's Disease of Bone and Related Disorders is a 501c3 voluntary health agency that addresses several benign bone disorders and the skeletal complications of malignancy. The benign disorders include: Paget's disease of bone, hyperparathyroidism, osteopetrosis (not the more common disorder osteoporosis) and fibrous dysplasia. The Foundation provides information and programs for patients and health professionals and advocates for increased research funding for these disorders.

The Foundation was founded in 1978. Information is available on the Foundation website at www.paget.org.

The University of Virginia School of Medicine has planned and implemented this program in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Virginia School of Medicine and The Paget Foundation. The University of Virginia School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Virginia School of Medicine designates this educational activity for a maximum of 19 category 1 credits towards the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

The University of Virginia School of Medicine awards 0.1 CEU per contact hour to each non-physician participant who successfully completes this educational activity. The CEU (Continuing Education Unit) is a nationally recognized unit of measure for continuing education and training activities that meet specific educational planning requirements. The Paget Foundation maintains a permanent record of participants who have been awarded CEUs.

Registration for the symposium will be available on line at www.paget.org and by mail or fax. Registration fee is \$200 US dollars and includes all handouts, symposium meals and CME credits.

Abstracts will be accepted until January 21, 2005. Abstract submission is available on line at www.paget.org. All approved abstracts will be eligible for poster presentation. After peer review, some abstracts may be selected for short oral presentations. Submission instructions as well as information about Young Investigator Awards may be found in the "Abstracts and Poster Information" section of this program. Abstract categories include:

- Prostate Cancer and Bone Metastases
- Breast Cancer and Bone Metastases
- Multiple Myeloma
- Osteosarcoma/Primary Bone Tumors
- Bone Pain
- Imaging Techniques
- Cancer Treatment Induced Bone Loss
- Current & Future Directions in Therapy
- Other topics related to the skeletal complications of malignancy and bone biology

Program

KEYNOTE SPEAKERS

ALFRED L. GOLDBERG, Ph.D.
HARVARD MEDICAL SCHOOL

“Functions of the Proteasome-From Protein Degradation and Immune Surveillance to Cancer Therapy”

ISAIAH J. FIDLER, D.V.M., Ph.D.
M.D. ANDERSON CANCER CENTER

“Biology and Antivascular Therapy of Bone Metastasis”

PROGRAM SESSIONS

*Please note: Exact session times and order of presentations will be determined at a later date.
Program is subject to change.

Multiple Myeloma

Targeting Myeloma in the Bone Marrow
Microenvironment
Kenneth C. Anderson, M.D.

Mechanisms of Bone Destruction in Myeloma
G. David Roodman, M.D., Ph.D.

Role of DDK1 in Osteoblast Suppression in Myeloma
John D. Shaughnessy, Ph.D.

Role of Intensive Therapy in Myeloma and Myeloma
Bone Disease
Bart Barlogie, M.D., Ph.D.

Breast Cancer

Overview of Mechanisms of Bone Metastases in Breast
Cancer and IL8 studies
Larry J. Suva, Ph.D.

The Role of Tumor-Associated Macrophages in
Metastasis-Associated Osteolysis
Nicholas A. Athanasou, Ph.D., M.B.B.S.

Non-hormonal Management of Metastatic Breast Cancer
Gabriel Hortobagyi, M.D., F.A.C.P.

Bone Markers in Breast Cancer
Allan Lipton, M.D.

Review of Oral and iv Bisphosphonates in Metastatic
Breast Cancer
JJ Body, M.D., Ph.D.

Prostate Cancer

A Multidisciplinary Approach to Treating the
Tumor-Microenvironment Interactions of Metastatic
Prostate Cancer
Kenneth J. Pienta, M.D.

The Bone Marrow Microenvironment: Modulation by
Parathyroid Hormones and Support of Prostate Cancer
Localization
Laurie McCauley, D.D.S., Ph.D.

ETA Antagonists in Prostate Cancer and the
Relationship to Bone Metastasis
Joel B. Nelson, M.D.

Molecular Mechanisms of Osteoblastic Bone Metastases
Theresa A. Guise, M.D.

lications of Malignancy

Program

Primary Bone Tumors/Osteosarcoma

The Influence of Metastatic Tumors on Bone Cell Proliferation and Differentiation
Gary S. Stein, Ph.D.

Genetic Mutations and Other Factors Related to Pathogenesis in Osteosarcoma
Marc Hansen, Ph.D.

Osteosarcoma Arising in Benign Bone Disease: Paget's Disease of Bone and Fibrous Dysplasia
Frederick R. Singer, M.D.

Future Directions in the Treatment of Osteosarcoma
Kristy Weber, M.D.

Measuring and Treating Pain in Cancer/New Directions in Imaging

Pain Associated with Cancer and Bone Metastases
Denis R. Clohisy, M.D.

An Algorithm Model for Pain
Ronald H. Blum, M.D.

Assessing Pain Related to Cancer and Bone Metastases
Charles S. Cleeland, Ph.D.

Bone Metastases Imaging by Bioluminescence
Gabri Van der Pluijm, Ph.D.

Detection and Quantification of Secondary Tumors and Tissue Destruction in Mouse Models of Cancer
Ellen Filvaroff, Ph.D.

Cancer Treatment Induced Bone Loss

Treatment-Related Osteoporosis in Prostate Cancer Survivors
Matthew Smith, M.D., Ph.D.

Bone Marrow Transplantation and Bone Loss
Peter R. Ebeling, M.D., FRACP

Aromatase Inhibitors in Cancer Treatment Induced Bone Diseases
Kathy Weilbaeher, M.D.

Current & Future Directions in Treatment

Novel Mechanisms and Applications of Bisphosphonate Treatment
Jonathan Green, M.D.

Adjuvant Therapy/Use of Bisphosphonates to Prevent Metastatic Cancer
Alexander Paterson, M.D.

Antibody to RANK Ligand-Overview of OPG Ligand
David L. Lacey, M.D.

Disclosure of Discussion of non-FDA approved uses for pharmaceutical products and/or medical devices:

The University of Virginia School of Medicine, as an ACCME provider, requires that all faculty presenters identify and disclose any "off label" or investigational uses for pharmaceutical and medical device products. The University of Virginia School of Medicine recommends that each physician fully review all the available data on new products or procedures prior to instituting them with patients.

Disclosure of faculty financial affiliations:

As a provider accredited by the Accreditation Council for Continuing Medical Education, the Office of Continuing Medical Education of the University of Virginia School of Medicine must insure balance, independence, objectivity and scientific rigor in all its individually sponsored or jointly sponsored educational activities. All faculty participating in a sponsored activity are expected to disclose to the activity audience any significant financial interest or other relationship (1) with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity (significant financial interest or other relationship can include such things as grants or research support, employee, consultant, major stock holder, member of speakers bureau, etc.). The intent of this disclosure is not to prevent a speaker with a significant financial or other relationship from making a presentation, but rather to provide listeners with information on which they can make their own judgments. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion.

Abstract and Poster Information

Accessing the On Line Abstract Submission Program

The Skeletal Complications of Malignancy IV abstract submission process may be accessed via the symposium website at www.paget.org. The submission process is user friendly and a fast and easy way to submit your abstract and receive confirmation of its acceptance.

Submission Deadline

Abstracts must be submitted by January 21, 2005.

It is your responsibility to ensure that the abstract is entered online by the deadline. We recommend entering your abstract prior to January 21, 2005, to avoid any delays.

Technical Support

The Online Submission Program uses a password gate that protects the confidentiality and integrity of your abstract. It also includes some Frequently Asked Questions (FAQs) regarding the online submission process, as well as instructions that lead you through the submission process. In addition, every page within the submission process contains a Help button (located in the upper right hand corner of the browser window). If you need additional technical support, please e-mail support@abstractsonline.com, call (217) 398-1792, or send a fax to (217) 355-0101. Live technical support is available M-F from 9am-5pm Central Time.

Poster Display Sessions

All accepted abstracts will be eligible for poster presentation at the symposium. The poster boards will be 6ft. wide x 4ft. tall and will be made available the first morning of the symposium during registration. Specific times for poster sessions will be available in the final program information. We ask that you or a colleague who is familiar with the data be available at the poster site during the designated time. You will be assigned an abstract number for placement on the poster board upon registration at the symposium.

Young Investigator Award

After all abstracts are peer reviewed, the symposium will recognize up to two young investigators for their excellence in research. A travel grant as well as waived fees to the symposium will be provided to the individual(s) chosen. These awards are given to individuals who are within five years of completion of a Ph.D. or residency training for M.D. or their equivalent. The five years of eligibility are defined to extend from the end of the calendar year of the applicants graduation date or residency completion. The young investigator who receives this award will be notified approximately 14-21 days after the abstract deadline of January 21, 2005.

Abstracts Processing Vendor

The abstracts processing vendor for the Skeletal Complications of Malignancy IV is OASIS by Coe-Truman Technologies, Inc. (CTT). When making *abstract-related* inquiries, please contact OASIS support at:

Skeletal Complications of Malignancy IV
c/o Oasis Technical Support
Tel: (217) 398-1792
Fax: (217) 355-0101
E-mail: support@abstractsonline.com

Complications of Malignancy

Travel Information

Meeting Venue

Natcher Conference Center
(Meeting Venue)
45 Center Drive
Bethesda, MD 20892

The Natcher Conference Center is located on the campus of the National Institutes of Health. The venue is handicap accessible. There is limited parking and attendees are encouraged to take the Metro system to the Medical Center stop via the Red Line.

Please be advised that the Natcher Conference Center enforces security screening (similar to airport procedures) and a photo ID will be required to access the building. Questions may be addressed to the Natcher Center at (301)594-7307.

Hotel Information

Hyatt Regency Bethesda
One Bethesda Metro Center
Wisconsin Avenue at Old
Georgetown Road
Bethesda, MD 20814

Reservations: (800) 233-1234 or
(301) 657-1234

Symposium Rates:
Single/Double-\$159.00

Above prices, which exclude tax, are valid April 27-30, 2005 and must be made by April 1, 2005. After this time, reservations will be made on space available basis at the hotel's prevailing rates. All reservations must be made directly with the Hotel's Reservation Department at the numbers listed above. Please refer to the event by "Skeletal Complications of Malignancy."

Airport Information

Bethesda, Maryland is accessible from 3 area airports:

Washington Reagan Airport
National—
30 minutes

Dulles International Airport—
30 minutes

Baltimore Airport (BWI)—
45 minutes to 1 hour

Additional travel information will be provided at a later date.

For information contact:

The Paget Foundation
120 Wall Street, Suite 1602
New York, NY 10005-4001

Telephone: 212-509-5335 • Fax: 212-509-8492 • Email: pagetsym@aol.com
Website: www.paget.org

Skeletal Complications of Malignancy

IV

Faculty

Kenneth C. Anderson, M.D.
Dana Farber Cancer Institute
Boston, MA

Nicholas A. Athanasou, Ph.D., MBBS
Nuffield Orthopaedic Centre
Oxford, United Kingdom

Bart Barlogie, M.D., Ph.D.
University of Arkansas for Medical
Sciences
Little Rock, AR

Ronald H. Blum, M.D.
Beth Israel Medical Center
New York, NY

Jean-Jacques Body, M.D., Ph.D.
Institut Jules Bordet
Université Libre de Bruxelles
Brussels, Belgium

Charles S. Cleeland, Ph.D.
MD Anderson Cancer Center
Houston, TX

Denis R. Clohisy, M.D.
University of Minnesota Medical
School and Cancer Center
Minneapolis, MN

Peter R. Ebeling, M.D., FRACP
The Royal Melbourne Hospital
Victoria, Australia

Isaiah J. Fidler, DVM, Ph.D.
MD Anderson Cancer Center
Houston, TX

Ellen H. Filvaroff, Ph.D.
Genentech, Inc.
San Francisco, CA

Jonathan Green, Ph.D.
Novartis Pharmaceuticals AG
Basel, Switzerland

Alfred L. Goldberg, Ph.D.
Harvard Medical School
Boston, MA

Theresa A. Guise, M.D.
University of Virginia
Charlottesville, VA

Marc F. Hansen, Ph.D.
University of Connecticut Health
Center
Farmington, CT

Gabriel Hortobagyi, M.D., F.A.C.P.
MD Anderson Cancer Center
Houston, TX

David L. Lacey, M.D.
Amgen, Inc.
Thousand Oaks, CA

Allan Lipton, M.D.
Milton S. Hershey Medical Center
Hershey, PA

Laurie McCauley, D.D.S., Ph.D.
University of Michigan Dental School
Ann Arbor, MI

Joel B. Nelson, M.D.
University of Pittsburgh
Pittsburgh, PA

Alexander Paterson, M.D.
Tom Baker Cancer Center
Calgary, Canada
University of Michigan
Ann Arbor, MI

Kenneth Pienta, M.D.
University of Michigan Comprehensive
Cancer Center
Ann Arbor, MI

G. David Roodman, M.D., Ph.D.
University of Pittsburgh
Pittsburgh, PA

John D. Shaughnessy, Ph.D.
Arkansas Cancer Research Center
Little Rock, AR

Frederick R. Singer, M.D.
John Wayne Cancer Institute
Santa Monica, CA

Matthew Smith, M.D., Ph.D.
Massachusetts General Hospital
Boston, MA

Gary S. Stein, Ph.D.
University of Massachusetts Medical
Center
Worcester, MA

Larry J. Suva, Ph.D.
University of Arkansas for Medical
Sciences
Little Rock, AR

Gabri Van der Pluijm, Ph.D.
Leiden University Medical Center
Leiden, The Netherlands

Kristy Weber, M.D.
Johns Hopkins Outpatient Center
Baltimore, MD

Katherine Weilbaecher, M.D.
Washington University School of
Medicine
St. Louis, MO

Program

Please contact the symposium organizers for more information at:

The Paget Foundation
120 Wall Street, Suite 1602, New York, NY 10005
(T) 212-509-5335 • (F) 212-509-8492 • www.paget.org • E-mail: Pagetsym@aol.com